Research In Cancer and Tumor
2015; 4(1): 1-6
doi:10.5923/j.rct.20150401.01
Valeria P. Careaga1, 2, Paula A. Sacca1, Osvaldo N. Mazza3, 4, Carlos Scorticati3, Gonzalo Vitagliano4, Sabrina Johanna Fletcher1, Marta S. Maier2, Juan C. Calvo1, 5
1Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina
2UMYMFOR (CONICET-UBA), Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina
3Hospital de Clínicas “José de San Martín”, Cátedra de Urología,Facultad de Medicina, Universidad de Buenos Aires, Argentina
4Hospital Alemán, Servicio de Urología, Buenos Aires, Argentina
5Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, UBA, Ciudad Universitaria, Buenos Aires, Argentina
Correspondence to: Juan C. Calvo, Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina.
Email: |
Copyright © 2015 Scientific & Academic Publishing. All Rights Reserved.
The aim of this study was to determine fatty acid composition in periprostatic adipose tissue (PPAT) of patients undergoing surgery for either prostatic cancer or benign prostatic hyperplasia (BPH). PPAT were obtained from 12 patients undergoing radical prostatectomy for clinically localized prostate tumors (TPPAT, age range 55-70 years) and 11 patients undergoing adenomectomy for BPH (BPPAT, age range 57-79 years). Fatty acid methyl esters of total lipids of PPAT were processed and then analyzed by gas chromatography-mass spectrometry. Quantitation was performed by comparing the percentage area of each FAME peak on the chromatogram with that of the internal standard of known weight, and expressed as percentage of total fatty acids. There were differences in fatty acid content of PPAT, with higher levels of palmitic acid (16:0; P = 0.036) and dihomo-gammalinolenic acid (20:3 n-6; P = 0.020) and lower levels of arachidonic acid (20:4 n-6; P = 0.030) in prostate cancer PPAT, along with a higher 20:4/20:3 (P = 0.001) and lower 20:3/18:2 (P = 0.027) fatty acid ratio in benign prostate hyperplasia PPAT. To the best of our knowledge, this study represents the first attempt at comparing periprostatic fat pad lipid composition in different prostate pathologies. Fatty acid analysis and lipidomics may be important tools to further understand events that occur in tumor microenvironment during prostate cancer disease.
Keywords: Prostate cancer, Benign prostate hyperplasia, Periprostatic adipose tissue, Fatty acids, Lipid composition, Lipidomics
Cite this paper: Valeria P. Careaga, Paula A. Sacca, Osvaldo N. Mazza, Carlos Scorticati, Gonzalo Vitagliano, Sabrina Johanna Fletcher, Marta S. Maier, Juan C. Calvo, Fatty Acid Composition of Human Periprostatic Adipose Tissue from Argentine Patients and Its Relationship to Prostate Cancer and Benign Prostatic Hyperplasia, Research In Cancer and Tumor, Vol. 4 No. 1, 2015, pp. 1-6. doi: 10.5923/j.rct.20150401.01.
|
[1] | Instituto Nacional del Cancer, Ministerio de Salud, Argentina (2012) Available:http://www.msal.gov.ar/inc/index.php/acerca-del-cancer/estadisticas. Last accessed 01/22/2015. |
[2] | Gross RW, Xianlin H.. Lipidomics at the Interface of Structure and Function in Systems Biology. Chem Biol 2011; 18: 284–1. |
[3] | Zhou X, Mao J, Ai J, Deng Y, Roth MR, Pound C, Henegar J, Welti R, Bigler SA. Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics. PLOS ONE 2012; 7: e48889. |
[4] | Lopez Fontana C, Maselli Artola ME, Vanrell Rodriguez MC, Di Milta Monaco NA, Perez Elizalde R, López Laur JD. Advances on the influence of adipose tissue on prostate cancer. Actas Urol Esp 2009; 33: 242-8. |
[5] | Niclis C, Diaz MP, Eynard AR, Roman MD, La Vecchia C. Dietary habits and prostate cancer prevention: a review of observational studies by focusing on South America. Nutr Cancer 2012; 64: 23-3. |
[6] | Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol 2010; 7: 442-3. |
[7] | Schumacher MC, Laven B, Petersson F, Cederholm T, Onelöv E, Ekman P, Brendler C. A comparative study of tissue ω-6 and ω-3 polyunsaturated fatty acids (PUFA) in benign and malignant pathologic stage pT2a radical prostatectomy specimens. Urol Oncol 2013; 31: 318-4. |
[8] | Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 2004; 24: 821-7. |
[9] | Kim BH, Kim CI, Chang HS, Choe MS, Jung HR, Kim DY, Park CH. Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer?. Korean J Urol 2011; 52: 253-9. |
[10] | van Roermund JG, Hinnen KA, Tolman CJ, Bol GH, Witjes JA, Bosch JL, Kiemeney LA, van Vulpen M. Periprostatic fat correlates with tumor aggressiveness in prostate cancer patients. BJU Int 2001; 107: 1775-9. |
[11] | Bhindi B, Trottier G, Elharram M, Fernandes KA, Lockwood G, Toi A, Hersey KM, Finelli A, Evans A, van der Kwast TH, Fleshner NE. Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int 2012; 110: 980-6. |
[12] | Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol. 2009; 182: 1621-7. |
[13] | Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Pina F, Mota-Pinto A, Lopes C, Medeiros R. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res 2012; 31: 32-43 |
[14] | Sacca PA, Creydt VP, Choi H, Mazza ON, Fletcher SJ, Vallone VB, Scorticati C, Chasseing NA, Calvo JC. Human periprostatic adipose tissue: its influence on prostate cancer cells. Cell Physiol Biochem 2012; 30: 113-2. |
[15] | Ribeiro R, Monteiro C, Catalán V, Hu P, Cunha V, Rodríguez A, Gómez-Ambrosi J, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Pina F, Lopes C, Medeiros R, Frühbeck G. Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. BMC Med 2012; 10: 108-121 |
[16] | Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-9. |
[17] | Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A. Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes. Neoplasia 2009; 11: 692-9. |
[18] | Suburu J, Chen YQ. Lipids and prostate cancer. Prostaglandins Other Lipid Mediat 2012; 98: 1-10. |
[19] | Bozza PT, Viola JP. Lipid droplets in inflammation and cancer. Prostaglandins Leukot.Essent.Fatty Acids 2010; 82: 243-0. |
[20] | Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-0. |
[21] | Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and its regulation. Annu Rev Biochem 1983; 52: 537-9. |
[22] | Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J.Cancer 2002; 98: 19-2. |
[23] | Jones AC, Trujillo KA, Phillips GK, Fleet TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK, Fischer EG, Bisoffi M. Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. Prostate 2012; 72: 1159-0. |
[24] | Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57: 176-0. |
[25] | Chaudry A, McClinton S, Moffat LE, Wahle KW. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991; 64: 1157-0. |
[26] | Faas FH, Dang AQ, White J, Schaefer RF, Johnson DE. Decreased prostatic arachidonic acid in human prostatic carcinoma. BJU Int 2003; 92: 551-4. |
[27] | Sprecher H. Biochemistry of essential fatty acids. Prog Lipid Res 1981; 20: 13-2. |
[28] | Kelavkar U, Lin Y, Landsittel D, Chandran U, Dhir R. The yin and yang of 15-lipoxygenase-1 and delta-desaturases: dietary omega-6 linoleic acid metabolic pathway in prostate. J Carcinog 2006; 5: 9-14. |
[29] | Garaulet M, Pérez-Llamas F, Pérez-Ayala M, Martínez P, de Medina FS, Tebar FJ, Zamora S. Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area: relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr 2001; 74: 585-1. |
[30] | Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, Kranidis A. Prostate cáncer vs hiperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Lekot Essent Fatty Acids 2002; 66: 467-7. |
[31] | Chaldakov GN, Beltowsky J, Ghenev PI, Fiore M, Panayotov P, Rančič G, Aloe L. Adipoparacrinology--vascular periadventitial adipose tissue (tunica adiposa) as an example. Cell Biol Int 2012; 36: 327-30. |